GLP-1 Market
LLY $1179.27 ▲ +0.8% NVO $38.64 ▲ +1.2% PFE $28.28 ▲ +1.7% VKTX $28.51 ▲ +2.8% KLRA $11.61 ▲ +16.1% GPCR $25.54 ▼ -0.5% RHHBY $54.09 ▲ +1.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HRS-7249

HRS-7249

Company
Fujian Shengdi Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for HRS-7249 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07799688

    A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 400 participants Est. completion 2028-10-15 2 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT06541457

    A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 48 participants Est. completion 2025-07-30 1 site Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Active, not recruiting NCT NCT07100418

    A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 224 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Active, not recruiting NCT NCT07308392

    Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 119 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: HRS-7249, HRS-7249 Injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.